9 November 2020

ASX Announcement

NOTIFICATION OF EXPIRED OPTIONS

MELBOURNE Australia, 9 November 2020: AdAlta Limited (ASX:1AD), advises a total of 834,472 unlisted options have expired. Details of the expired options are outlined below.

Details	Number	Exercise Price	Expiry Date	ASX Code
Unlisted options	600,000	$0.1685	16 October 2020	1ADAD
Unlisted options	234,472	$0.1685	1 November 2020	1ADAD

Set out below is an updated capital structure of the Company following the expiry of options.

Details	Number	Exercise Price	Expiry Date	ASX Code
Ordinary Shares	245,175,853	N/A	N/A	1AD
Listed options	23,348,803	$0.2485	30/06/2021	1ADO
Unlisted options	400,000	$0.2485	14/11/2021	1ADAD
Unlisted options	130,000	$0.4985	14/11/2021	1ADAD
Unlisted options	100,000	$0.7485	14/11/2021	1ADAD
Unlisted options	100,000	$0.9985	14/11/2021	1ADAD
Unlisted options	620,535	$0.2385	27/02/2022	1ADAD
Unlisted options	4,929,060	$0.2485	26/11/2025	1ADAD
Unlisted options	600,000	$0.0835	20/03/2023	1ADAE

Authorised for lodgement by:

Tim Oldham
CEO and Managing Director
November 2020

Notes to Editors
About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions. The i-body technology mimics the shape and stability of a unique and versatile antigen-binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta is conducting a Phase 1 clinical trial for its lead i-body candidate, AD-214. AD-214 is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with multi-national company GE Healthcare for discovery of a diagnostic imaging agent against Granzyme B for use in immuno-oncology.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

For more information, please contact:

Investors

Tim Oldham, CEO & Managing Director
Tel: +61 403 446 665
E: t.oldham@adalta.com.au

Media

IR Department
Tel: +61 411 364 382
E: gabriella.hold@irdepartment.com.au